Teva/Ivax merger
This article was originally published in The Tan Sheet
Executive Summary
FTC continues to review the consent order signed by Teva Pharmaceutical and Ivax; however, the firms have "no reason to believe that the acceptance will not be forthcoming shortly," the two firms announce Jan. 10. The acquisition of Ivax by Teva is expected close on the third business day following the firms' announcement that FTC has accepted the order, they add. The deal previously was expected to close Jan. 12, and now is anticipated to close "later this month." The acquisition was announced in August (1"The Tan Sheet" Aug. 1, 2005, p. 11)...
You may also be interested in...
Teva Broadens Private Label OTC Offerings With Ivax Acquisition
Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.